MaxCyte, Inc. (MXCT) Free cash flow
- Free cash flow · 12 months (USD): Value $-23.64M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -125.57%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-23.64M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-22.98M − $665.00K ≈ $-23.64M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -125.57% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-23.64M ÷ $18.83M × 100 ≈ -125.57% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-22.98M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.64× | Operating cash flow / net income. Period ending 2026-06-30. $-22.98M ÷ $-35.64M ≈ 0.64× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -22.98M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 665.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -23.64M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 18.83M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -35.64M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-23.64M | (m) | $-22.98M | $665.00K | (m) | $18.83M | (m) | $-35.64M | (m) | (m) | -125.57% | 0.64× |
| 2026-03-31 | $-29.36M | (m) | $-28.17M | $1.19M | (m) | $19.71M | (m) | $-39.12M | (m) | (m) | -148.90% | 0.72× |
| 2025-12-31 | $-36.18M | (m) | $-34.41M | $1.77M | (m) | $20.96M | (m) | $-44.63M | (m) | (m) | -172.63% | 0.77× |
| 2025-09-30 | $-41.23M | (m) | $-39.54M | $1.68M | (m) | $22.23M | (m) | $-45.63M | (m) | (m) | -185.49% | 0.87× |
| 2025-06-30 | $-38.27M | (m) | $-36.48M | $1.79M | (m) | $23.23M | (m) | $-44.77M | (m) | (m) | -164.69% | 0.81× |
| 2025-03-31 | $-32.96M | (m) | $-31.46M | $1.50M | (m) | $22.37M | (m) | $-41.79M | (m) | (m) | -147.30% | 0.75× |
| 2024-12-31 | $-29.26M | (m) | $-27.61M | $1.65M | (m) | $22.21M | (m) | $-41.05M | (m) | (m) | -131.72% | 0.67× |
| 2024-09-30 | $-21.23M | (m) | $-18.81M | $2.42M | (m) | $20.92M | (m) | $-35.74M | (m) | (m) | -101.49% | 0.53× |
| 2024-06-30 | $-25.39M | (m) | $-22.66M | $2.73M | (m) | $19.46M | (m) | $-35.43M | (m) | (m) | -130.46% | 0.64× |
| 2024-03-31 | $-30.87M | (m) | $-27.93M | $2.95M | (m) | $20.12M | (m) | $-36.57M | (m) | (m) | -153.46% | 0.76× |
| 2023-12-31 | $-25.39M | (m) | $-21.69M | $3.70M | (m) | $19.50M | (m) | $-37.92M | (m) | (m) | -130.20% | 0.57× |
| 2023-09-30 | $-33.73M | (m) | $-28.75M | $4.98M | (m) | $22.50M | (m) | $-37.45M | (m) | (m) | -149.93% | 0.77× |
| 2023-06-30 | $-34.17M | (m) | $-26.44M | $7.74M | (m) | $25.50M | (m) | $-32.64M | (m) | (m) | -134.04% | 0.81× |
| 2023-03-31 | $-29.45M | (m) | $-15.41M | $14.04M | (m) | $26.86M | (m) | $-30.39M | (m) | (m) | -109.66% | 0.51× |
| 2022-12-31 | $-33.26M | (m) | $-14.78M | $18.48M | (m) | $28.75M | (m) | $-23.57M | (m) | (m) | -115.69% | 0.63× |
| 2022-09-30 | $-27.06M | (m) | $-9.66M | $17.40M | (m) | $28.50M | (m) | $-23.64M | (m) | (m) | -94.96% | 0.41× |
| 2022-06-30 | $-19.79M | (m) | $-4.43M | $15.37M | (m) | $26.95M | (m) | $-19.88M | (m) | (m) | -73.44% | 0.22× |
| 2022-03-31 | $-19.26M | (m) | $-9.73M | $9.53M | (m) | $24.19M | (m) | $-16.04M | (m) | (m) | -79.61% | 0.61× |
| 2021-12-31 | $-14.51M | (m) | $-10.68M | $3.83M | (m) | $21.57M | (m) | $-19.08M | (m) | (m) | -67.28% | 0.56× |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-15.86M | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-10.85M | (m) | $-8.78M | $2.07M | (m) | $15.45M | (m) | $-11.82M | (m) | (m) | -70.25% | 0.74× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-10.07M | (m) | $-8.80M | $1.27M | (m) | $13.26M | (m) | $-12.89M | (m) | (m) | -75.99% | 0.68× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |